Outsourcing Pharma
FEBRUARY 7, 2022
The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.
pharmaphorum
FEBRUARY 7, 2022
The last three years in pharma have seen a growing awareness of and dissatisfaction with a trend that has plagued the industry for its whole life: Nondiverse and unrepresentative clinical trials, which lead to incomplete data and compounded health disparity for minority populations. It’s been more than a year since the US Food and Drug Administration released its final guidance on diversifying clinical trials in November 2020.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
FEBRUARY 7, 2022
An expert from the CRO discusses the role real-world data plays in developing therapies, with benefits ranging from speeding recruitment to decreasing costs.
pharmaphorum
FEBRUARY 7, 2022
The UK government’s long-awaited plan to tackle the backlog in NHS care caused by the pandemic has been delayed, but one small part that aims to improve transparency has been revealed. Patients who need non-urgent surgery will be able to use a new platform on the NHS.UK website – called My Planned Care – to get information about waiting times for their trust.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
FEBRUARY 7, 2022
The collaboration between the trial tech company and heathcare firm is aimed at increasing study access at MinuteClinic locations using Medableâs software.
pharmaphorum
FEBRUARY 7, 2022
Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline’s PD-1 inhibitor Jemperli via the Cancer Drugs Fund (CDF). The health technology assessment (HTA) agency has given a temporary okay to the use of Jemperli (dostarlimab) for endometrial cancer patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mutations, while additional evidence for the drug&#
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
FEBRUARY 7, 2022
Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US. The complement C1s-targeting antibody – given the brand name Enjaymo – has been cleared decrease the need for blood transfusions in patients with CAD, an autoimmune disease which results in destruction of red blood cells (haemolysis).
Pharma Times
FEBRUARY 7, 2022
Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes
pharmaphorum
FEBRUARY 7, 2022
Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision comes right on the heels of the FDA’s rejection of Merck & Co’s rival oral P2X3 antagonist gefapixant, which was also attributed to concerns about the safety of the drug.
Pharma Times
FEBRUARY 7, 2022
Extensive research into pharmacy responses across Europe during the pandemic yields several recommendations
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
107 
Let's personalize your content